KOSDAQBiotech & Pharma064550

Bioneercorporation

₩5,970▼ 0.67%2026-11-18 close
Market Cap
₩154.1B
Turnover
₩700M
Volume
110K
Shares out.
25.8M
PER
—
PBR
0.9×
EPS
-₩519
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Quarterly Losses Return After Annual Turnaround

Despite an annual operating profit turnaround in 2025, a wider third-quarter 2026 operating loss and net loss attributable to controlling shareholders make sustained quarterly profitability the key point to watch at BIONEER CORPORATION.

  1. 1

    Operating profit was KRW 15.2 billion in 2025, turning positive from an operating loss of KRW 13.4 billion in 2024, and revenue of KRW 330.1 billion was the largest year in 2022–2025.

  2. 2

    Third-quarter 2026 operating loss was KRW 4.01 billion and net loss attributable to controlling shareholders was KRW 7.72 billion, marking five straight loss-making quarters since Q3 2025.

  3. 3

    Probiotics made up 93% of revenue in Q1 2025, up from 84.7% in 2023, so earnings are increasingly concentrated in one business.

  4. 4

    The debt ratio (total liabilities ÷ total equity) rose from 22.7% in 2022 to 63.0% in 2025.

  5. 5

    PER cannot be calculated because the last four quarters were net losses, while PBR sits below 1x.

02

Business structure

BIONEER CORPORATION runs a molecular diagnostics business based on genetic reagents and test kits at the parent level, and has grown a probiotics business through its subsidiary Acebiome. Probiotics accounted for 84.7% of company revenue in 2023 and rose to 93% in Q1 2025.

Its flagship product is a functional probiotic for body-fat reduction, and the subsidiary's 2024 revenue was KRW 268.8 billion, up 14.6%. Many similar competing products have launched in that market, but the company says it keeps the number one market share.

Parent-level revenue comes from molecular diagnostics and related bio businesses, and cumulative revenue for DNA and RNA genetic reagents and test kits was KRW 16.4 billion in the first nine months of 2025.

The diagnostics business shrank after the COVID-19 boom, with parent-level revenue falling from KRW 158.2 billion in 2020 to KRW 40 billion in 2023. Its hair-loss functional cosmetic was filed for Korean approval in 2019 but was returned for review in 2021 and again in May 2025, delaying domestic launch.

The company then shifted to an overseas-first strategy, with sales reported in 13 countries including the United States, the United Kingdom, Germany, France and Japan. The business mix splits into a cash-generating probiotics unit, a recovering diagnostics unit, and a cosmetic unit waiting on approval.

Unlike large listed pharma companies that describe growth through drug pipelines, this company's earnings center on health functional food sales.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩88.1B₩2.9B3.3%
2025Q4₩79.9B₩2.7B3.4%
2026Q1₩81.8B-₩500M−0.6%
2026Q2₩96.2B₩1.2B1.2%
2026Q3₩83.3B-₩4B−4.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩218.4B₩11.5B₩12.1B5.3%5.1%22.7%
2023₩263.2B₩800M-₩10.6B0.3%−4.7%34.3%
2024₩294B-₩13.4B-₩20.6B−4.6%−9.6%46.4%
2025₩330.1B₩15.2B-₩2.8B4.6%−1.3%63.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 218.4 billion in 2022 to KRW 263.2 billion in 2023 (up 20.5% year on year), KRW 294 billion in 2024 (up 11.7%) and KRW 330.1 billion in 2025 (up 12.3%), marking three consecutive years of growth from 2023 to 2025.

Over the same period operating profit fell from KRW 11.5 billion in 2022 to KRW 792 million in 2023 (down 93.1%), then turned into an operating loss of KRW 13.4 billion in 2024. In 2025 operating profit returned to KRW 15.2 billion, with operating margin at 5.3% in 2022, 0.3% in 2023, -4.6% in 2024 and 4.6% in 2025.

The company attributed the 2025 improvement to a smaller inventory valuation provision, a reduced foreign exchange impact that eased bad-debt costs, higher probiotics sales, and lower personnel costs after the workforce cuts in the second half of 2024.

The 2024 loss was reported to reflect a KRW 11.3 billion inventory provision, a KRW 2.4 billion bad-debt provision tied to the currency spike, higher cost ratios for the flagship probiotic, and delayed domestic launch of the cosmetic.

Profit attributable to controlling shareholders was KRW 12.1 billion in 2022, then a net loss of KRW 10.6 billion in 2023, KRW 20.6 billion in 2024 and KRW 2.81 billion in 2025, so the loss narrowed last year.

Net profit including non-controlling interests was KRW 1.71 billion in 2025, a profit, while the controlling shareholders' share was a loss, so the two figures should be read together.

Operating cash flow was KRW 8.81 billion in 2022, KRW 4.14 billion in 2023, -KRW 13.5 billion in 2024 and KRW 10.3 billion in 2025, turning positive last year.

On a quarterly basis, Q3 2025 revenue of KRW 88.1 billion and operating profit of KRW 2.88 billion gave way to Q4 2025 revenue of KRW 79.9 billion (down 9.3% from the prior quarter) and operating profit of KRW 2.7 billion.

Q1 2026 revenue was KRW 81.8 billion with an operating loss of KRW 526 million, while Q2 2026 revenue rose to KRW 96.2 billion (up 17.5% quarter on quarter) with operating profit of KRW 1.18 billion.

Q3 2026 revenue fell to KRW 83.3 billion, down 13.4% from the prior quarter and 5.5% from a year earlier, and an operating loss of KRW 4.01 billion returned. The controlling shareholders' net loss widened to KRW 7.72 billion in Q3 2026, bringing the last four quarters' total to KRW 13.4 billion.

05

Industry analysis

Domestic diagnostics peers saw revenue fall back toward pre-COVID-19 levels after the pandemic boom, and BIONEER CORPORATION's parent-level diagnostics revenue followed the same path, according to press reports. One analysis read this as an industry-wide pattern rather than a company-specific failure.

The probiotics market is intensely competitive, with many functional probiotic products for body-fat reduction launched in recent years. The company says it keeps the number one share in that market, but earnings are concentrated in a single product, which makes it sensitive to competitive shifts.

Most countries prioritize domestic sales for cosmetics, so the company views Korean approval as important for credibility in overseas expansion. In March 2025, a Hana Securities analyst said the commercial success of the hair-loss cosmetic would be central to offsetting weak profitability in diagnostics.

The same report expected a return to profit in the second half of 2025, and full-year 2025 operating profit was later disclosed as positive.

Unlike large listed pharma and biotech companies that describe growth through pipeline milestones, this company's results depend mainly on health functional food and consumer product sales.

Its earnings therefore appear more exposed to consumer trends and distribution channel changes than to the average trajectory of the sector.

06

Outlook

The company said the second-quarter 2026 improvement came from scale effects of higher revenue rather than cost cuts. R&D spending on new drugs rose by about KRW 1.4 billion from the prior quarter in that period, and the core new-drug pipeline is in Phase 1b clinical trials.

However, third-quarter 2026 revenue fell and the operating loss widened to KRW 4.01 billion, so whether the second-quarter profit continues on a quarterly basis remains unconfirmed.

The hair-loss cosmetic was returned for review again in May 2025, and press reports say an objection was filed, making the domestic approval outcome a key checkpoint.

Overseas, the product is sold in 13 countries, and the company said in 2025 that it was preparing local review and sales networks for the probiotic in China and other markets. The company has presented overseas supply expansion and entry into new markets as drivers of earnings recovery.

Unlike a securities analyst view in 2025 that expected a second-half 2025 turnaround, the profit was confirmed on a full-year basis for 2025, while quarterly profit appeared only once, in Q2 2026. The direction of full-year 2026 results will be visible in the annual results expected around late February 2027. The confirmed figures will come with the 2026 annual business report, the next regular filing.

07

Valuation

PER
—
PBR
0.9×
ROE
-6.5%
EPS
-₩519
BPS
₩7,695
Dividend per share
₩0

Price-to-earnings cannot be calculated because the last four quarters were net losses. Price-to-book sits below 1x, meaning the shares trade under net assets attributable to controlling shareholders. Dividends provide virtually no support to the share price.

Total equity was KRW 227 billion at the end of 2025, of which equity attributable to controlling shareholders was KRW 209.7 billion. While the company remains loss-making, comparisons against net assets are the main reference point.

Revenue has grown in periods when profit did not follow, so the durability of earnings is a precondition for reading the valuation. Once profit accumulates into the black over several quarters, a price-to-earnings multiple becomes calculable.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Annual turnaround and revenue growth

Operating profit returned to KRW 15.2 billion in 2025, and revenue grew three straight years to KRW 330.1 billion. Q2 2026 revenue of KRW 96.2 billion and operating profit of KRW 1.18 billion showed one quarter of profit. The company attributes the gain to scale effects rather than cost cuts.

Cash-generating probiotics unit

The subsidiary's 2024 revenue reached KRW 268.8 billion, up 14.6%, and probiotics made up 93% of revenue in Q1 2025. The company says its flagship probiotic keeps the number one share and describes the unit as a cash cow. Its ability to offset weakness in parent-level diagnostics is cited as a basis for recovery.

Headcount reduction and lower fixed costs

Headcount at the end of the first half of 2025 was 393, down 31% from 569 at the end of 2024, and payroll fell from KRW 16.9 billion to KRW 12.3 billion over the same period. The company cited lower personnel costs after the second-half 2024 cuts as a 2025 profit driver. With fixed costs reduced, the company says higher revenue should lift profit faster.

09

Bear factors

Quarterly losses return

Operating loss returned in Q1 2026 at KRW 526 million, a profit followed in Q2, and Q3 brought a KRW 4.01 billion operating loss again. The controlling shareholders' net loss widened to KRW 7.72 billion in Q3, and losses have run for five straight quarters since Q3 2025. Revenue fell from the prior quarter while losses grew, which is the core bearish point.

Rising financial burden

The debt ratio rose from 22.7% in 2022 to 63.0% in 2025, with total liabilities of KRW 142.9 billion at the end of 2025. Operating cash flow swung from -KRW 13.5 billion in 2024 to KRW 10.3 billion in 2025, but quarterly losses put that cash generation back to the test. Equity attributable to controlling shareholders stands at KRW 209.7 billion and shrinks as losses accumulate.

Delayed domestic approval of the cosmetic

The hair-loss cosmetic was filed for domestic approval in 2019, returned for review in 2021 and again in May 2025, and an objection was reported afterward. The domestic launch delay was cited as one reason behind the 2024 loss. Until a domestic approval decision, growth in the cosmetic business depends on overseas channels.

10

Risk factors

Regulatory approval

Domestic approval of the cosmetic depends on Ministry of Food and Drug Safety review, and the line between functional cosmetics and medicines was the core issue in the rejections. The company is pursuing an objection, and an unfavorable result would close the domestic sales path. Overseas sales also depend on each country's regulatory environment.

Concentration and competition

With probiotics at 93% of revenue in Q1 2025, any slowdown in the flagship product's sales or margin would directly affect company-wide results. A higher cost ratio for that product was cited as a factor in the 2024 loss. Marketing needed to defend share in a crowded market could push selling and administrative costs up again.

Financial position and one-off costs

In 2024 a currency spike led to a KRW 2.4 billion bad-debt provision and a KRW 11.3 billion inventory provision was booked as cost. The smaller inventory provision in 2025 helped profit, but charges of this kind can recur. Total liabilities rising to KRW 142.9 billion is also a financial burden.

11

What to watch next

  1. After December 2026 (date not set)

    Outcome of the objection on domestic approval for the cosmetic. The result determines whether domestic sales of the cosmetic can expand.

  2. Late February 2027

    Full-year 2026 results disclosure. The 2025 annual results were disclosed on February 27, 2026, and whether Q4 2026 operating profit stays positive determines the full-year outcome.

  3. End of March 2027

    Filing of the 2026 annual business report, the next regular filing that confirms full-year profit and the net loss attributable to controlling shareholders.

  4. May 15, 2027

    Deadline for the Q1 2027 quarterly report (45 days after quarter end). Whether operating profit turns positive in Q1 2027 and breaks the quarterly loss pattern is the point to check.

12

Overall view

BIONEER CORPORATION returned to annual operating profit of KRW 15.2 billion in 2025, and revenue grew three straight years to KRW 330.1 billion. However, a third-quarter 2026 operating loss of KRW 4.01 billion and a controlling shareholders' net loss of KRW 7.72 billion pushed quarterly results back into losses.

The last four quarters total KRW 13.4 billion in net losses attributable to controlling shareholders, with five straight loss-making quarters since Q3 2025. On the bullish side, the cash-generating probiotics subsidiary, lower fixed costs after headcount cuts, and the Q2 2026 profit are cited as support.

On the bearish side, probiotics at 93% of revenue in Q1 2025 shows concentration, the debt ratio rose to 63.0%, and the cosmetic was returned for domestic approval. Price-to-earnings cannot be calculated and price-to-book sits below 1x, so the reading depends on whether profit accumulates again.

The next checkpoints are full-year 2026 profit in the 2026 annual business report and the direction of operating profit in the Q1 2027 quarterly report. This report is for information only and does not include buy or sell opinions.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. edaily.co.kr
  2. edaily.co.kr
  3. comp.fnguide.com
  4. globenewswire.com
  5. biontech.com
  6. newswire.co.kr
  7. globenewswire.com
  8. news.nate.com
  9. edaily.co.kr
  10. biospace.com
  11. hellodd.com
  12. mt.co.kr
  13. m.thebell.co.kr
  14. news.nate.com
  15. m.news.nate.com
  16. hellodd.com
  17. mt.co.kr
  18. marketin.edaily.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis